Galapagos Profile



Odds of Distress

Check how we calculate scores
Equity ratings for Galapagos NV are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 26, 2019 and ending today August 25, 2019. Click here to learn more.
USD 3.1  1.87%

Galapagos Summary

Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 837 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 8.76B. Galapagos NV conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 30.3M outstanding shares of which 658.73K shares are currently shorted by private and institutional investors with about 2.09 trading days to cover. N/A currently holds about 1.57B in cash with (181.41M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.83.
Check Galapagos Probability Of Bankruptcy

Ownership Allocation (%)

Galapagos Target Price Odds Analysis

Odds Below 162.97HorizonTargetOdds Above 162.97
52.89%30 days 162.97 46.98%
Based on normal probability distribution, the odds of Galapagos to move above current price in 30 days from now is about 46.98% (This Galapagos NV probability density function shows the probability of Galapagos Stock to fall within a particular range of prices over 30 days) .

Galapagos NV Top Holders

Galapagos NV Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Galapagos Key Fundamentals

Galapagos Against Markets

Galapagos Vital Trading Data

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 837 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Galapagos NV SEC Filings
Galapagos SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGalapagos NV
CEOOnno StolpeView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business AddressGeneraal De Wittelaan L11 A3
Foreign Associate  Austria
ExchangeBATS Exchange
Phone32 1 534 29 00
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestJuly 31, 2019

Did you try this?

Run World Markets Correlation Now


World Markets Correlation

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Galapagos Corporate Directors

Katrine Bosley Independent Non-Executive Director
Howard Rowe Non-Executive Independent Director
Harrold Barlingen Non-Executive Director
Please also check Risk vs Return Analysis. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.